Background Graft-versus-host disease (GVHD) results from recognition of host antigens by donor T cells following allogeneic hematopoietic cell transplantation (AHCT). Notably, histoincompatibility between donor and recipient is necessary but not sufficient to elicit GVHD. Therefore, we tested the hypothesis that some donors may be “stronger alloresponders” than others, and consequently more likely to elicit GVHD. Methods and Findings To this end, we measured the gene-expression profiles of CD4+ and CD8+ T cells from 50 AHCT donors with microarrays. We report that pre-AHCT gene-expression profiling segregates donors whose recipient suffered from GVHD or not. Using quantitative PCR, established statistical tests, and analysis of multiple independent training-test datasets, we found that for chronic GVHD the “dangerous donor” trait (occurrence of GVHD in the recipient) is under polygenic control and is shaped by the activity of genes that regulate transforming growth factor-β signaling and cell proliferation. Conclusions These findings strongly suggest that the donor gene-expression profile has a dominant influence on the occurrence of GVHD in the recipient. The ability to discriminate strong and weak alloresponders using gene-expression profiling could pave the way to personalized transplantation medicine.
References
[1]
Sykes M, Auchincloss H, Sachs DH (2004) Transplantation immunology. In: Paul WE, editor. Fundamental immunology. Philadelphia: Lippincott Williams & Wilkins. pp. 1481–1555.
[2]
Perreault C, Décary F, Brochu S, Gyger M, Bélanger R, et al. (1990) Minor histocompatibility antigens. Blood 76: 1269–1280.
[3]
Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, et al. (2005) Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: Requirements depend on target organ. Blood 105: 2227–2234.
[4]
Loveland B, Simpson E (1986) The non-MHC transplantation antigens: Neither weak nor minor. Immunol Today 7: 223–229.
[5]
Fischer-Lindahl K (1991) Minor histocompatibility antigens. Trends Genet 7: 219–224.
[6]
Fontaine P, Langlais J, Perreault C (1991) Evaluation of in vitro cytotoxic T lymphocyte assays as a predictive test for the occurrence of graft vs host disease. Immunogenetics 34: 222–226.
[7]
Martin PJ (1991) Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant 8: 217–223.
[8]
Gleichmann E, Pals ST, Rolink AG, Radaszkiewicz T, Gleichmann H (1984) Graft-versus-host reactions: Clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 5: 324–332.
[9]
Via CS, Shearer GM (1988) T-cell interactions in autoimmunity: Insights from a murine model of graft-versus-host disease. Immunol Today 9: 207–213.
[10]
Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, et al. (2004) Target antigens determine graft-versus-host disease phenotype. J Immunol 173: 5467–5475.
[11]
Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, et al. (2003) Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349: 2201–2210.
[12]
Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E (2004) Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 127: 479–490.
[13]
Biozzi G, Asofsky R, Lieberman R, Stiffel C, Mouton D, et al. (1970) Serum concentrations and allotypes of immunoglobulins in two lines of mice genetically selected for “high” or “low” antibody synthesis. J Exp Med 132: 752–764.
[14]
Biozzi G, Stiffel C, Mouton D, Bouthillier Y, Decreusefond C (1972) Cytodynamics of the immune response in two lines of mice genetically selected for “high” and “low” antibody synthesis. J Exp Med 135: 1071–1094.
[15]
Feingold N, Feingold J, Mouton D, Bouthillier Y, Stiffel C, et al. (1976) Polygenic regulation of antibody synthesis to sheep erythrocytes in the mouse: A genetic analysis. Eur J Immunol 6: 43–51.
[16]
Puel A, Mevel JC, Bouthillier Y, Feingold N, Fridman WH, et al. (1996) Toward genetic dissection of high and low antibody responsiveness in Biozzi mice. Proc Natl Acad Sci U S A 93: 14742–14746.
[17]
Blazar BR, Korngold R, Vallera DA (1997) Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 157: 79–109.
[18]
Teshima T, Ferrara JL (2002) Understanding the alloresponse: New approaches to graft-versus-host disease prevention. Semin Hematol 39: 15–22.
[19]
Vogelsang GB, Lee L, Bensen-Kennedy DM (2003) Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 54: 29–52.
[20]
Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, et al. (2002) A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 8: 32–39.
[21]
von Bueltzingsloewen A, Bélanger R, Perreault C, Bonny Y, Roy DC, et al. (1993) Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. Blood 81: 849–855.
[22]
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, et al. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18: 295–304.
[23]
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15: 825–828.
[24]
Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, et al. (2004) Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 10: 320–327.
[25]
Smyth KG (2005) Limma: Linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer. pp. 397–420.
[26]
Yang YH, Speed TP (2003) Design and analysis of comparative microarray experiments. In: Speed TP, editor. Statistical analysis of gene expression microarray data. Boca Raton: Chapman & Hall/CRC Press. pp. 35–91.
[27]
Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research. Oxford: Blackwell Science Ltd. 784 p.
[28]
Fukunaga K (1990) Introduction to statistical pattern recognition. San Diego: Academic Press. 592 p.
[29]
Duda RO, Hart PE, Stork DG (2001) Linear discriminant functions. Pattern classification. New York: John Wiley & Sons, Inc. pp. 215–281.
[30]
Baranzini SE, Mousavi P, Rio J, Caillier SJ, Stillman A, et al. (2005) Transcription-based prediction of response to IFNb using supervised computational methods. PLoS Biol 3: e2.. doi:10.1371/journal.pbio.0030002.
[31]
Yang YH, Speed T (2002) Design issues for cDNA microarray experiments. Nat Rev Genet 3: 579–588.
Goldrath AW, Luckey CJ, Park R, Benoist C, Mathis D (2004) The molecular program induced in T cells undergoing homeostatic proliferation. Proc Natl Acad Sci U S A 101: 16885–16890.
[34]
Allison DB, Cui X, Page GP, Sabripour M (2006) Microarray data analysis: From disarray to consolidation and consensus. Nat Rev Genet 7: 55–65.
[35]
Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, et al. (2003) Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 100: 1896–1901.
[36]
Miller LD, Long PM, Wong L, Mukherjee S, McShane LM, et al. (2002) Optimal gene expression analysis by microarrays. Cancer Cell 2: 353–361.
[37]
Evans EJ, Hene L, Sparks LM, Dong T, Retiere C, et al. (2003) The T cell surface—How well do we know it? Immunity 19: 213–223.
[38]
Korngold R, Sprent J (1983) Lethal GVHD across minor histocompatibility barriers: Nature of the effector cells and role of the H-2 complex. Immunol Rev 71: 5–29.
[39]
Perreault C, Roy DC, Fortin C (1998) Immunodominant minor histocompatibility antigens: The major ones. Immunol Today 19: 69–74.
[40]
Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, et al. (2001) Signatures of the immune response. Immunity 15: 375–385.
[41]
Kim JE, Kim SJ, Jeong HW, Lee BH, Choi JY, et al. (2003) RGD peptides released from big-h3, a TGF-β-induced cell-adhesive molecule, mediate apoptosis. Oncogene 22: 2045–2053.
[42]
Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006) Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 24: 99–146.
[43]
Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, et al. (2001) Evidence that furin is an authentic transforming growth factor-β1-converting enzyme. Am J Pathol 158: 305–316.
[44]
Park SR, Lee EK, Kim BC, Kim PH (2003) p300 cooperates with Smad3/4 and Runx3 in TGFβ1-induced IgA isotype expression. Eur J Immunol 33: 3386–3392.
[45]
Colland F, Jacq X, Trouplin V, Mougin C, Groizeleau C, et al. (2004) Functional proteomics mapping of a human signaling pathway. Genome Res 14: 1324–1332.
[46]
Chen F, Ogawa K, Nagarajan RP, Zhang M, Kuang C, et al. (2003) Regulation of TG-interacting factor by transforming growth factor-β. Biochem J 371: 257–263.
[47]
Thomas DA, Massague J (2005) TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369–380.
[48]
Woodgett JR (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17: 150–157.
[49]
Jung CG, Kim HJ, Kawaguchi M, Khanna KK, Hida H, et al. (2005) Homeotic factor ATBF1 induces the cell cycle arrest associated with neuronal differentiation. Development 132: 5137–5145.
[50]
Li O, Zheng P, Liu Y (2004) CD24 expression on T cells is required for optimal T cell proliferation in lymphopenic host. J Exp Med 200: 1083–1089.
[51]
Wright MD, Geary SM, Fitter S, Moseley GW, Lau LM, et al. (2004) Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 24: 5978–5988.
[52]
Ingvarsson S (1990) The myc gene family proteins and their role in transformation and differentiation. Semin Cancer Biol 1: 359–369.
[53]
Go WY, Liu X, Roti MA, Liu F, Ho SN (2004) NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment. Proc Natl Acad Sci U S A 101: 10673–10678.
[54]
Zhu M, John S, Berg M, Leonard WJ (1999) Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNγ-mediated signaling. Cell 96: 121–130.
[55]
Aplan PD, Lombardi DP, Kirsch IR (1991) Structural characterization of SIL, a gene frequently disrupted in T-cell acute lymphoblastic leukemia. Mol Cell Biol 11: 5462–5469.
[56]
Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I (2002) Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416: 183–187.
[57]
Utku N, Boerner A, Tomschegg A, Bennai-Sanfourche F, Bulwin GC, et al. (2004) TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response. J Immunol 173: 2342–2352.
[58]
Ideker T, Galitski T, Hood L (2001) A new approach to decoding life: Systems biology. Annu Rev Genomics Hum Genet 2: 343–372.
[59]
Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP (2005) Causal protein-signaling networks derived from multiparameter single-cell data. Science 308: 523–529.
[60]
Barry M, Bleackley RC (2002) Cytotoxic T lymphocytes: All roads lead to death. Nat Rev Immunol 2: 401–409.
[61]
Erez A, Perelman M, Hewitt SM, Cojacaru G, Goldberg I, et al. (2004) Sil overexpression in lung cancer characterizes tumors with increased mitotic activity. Oncogene 23: 5371–5377.
[62]
Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, et al. (1996) Analysis of T-cell repopulation after allogeneic bone marrow transplantation: Significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 87: 3984–3992.
[63]
Mathioudakis G, Storb R, McSweeney PA, Torok-Storb B, Lansdorp PM, et al. (2000) Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients. Blood 96: 3991–3994.
[64]
Guimond M, Busque L, Baron C, Bonny Y, Bélanger R, et al. (2000) Relapse after bone marrow transplantation: Evidence for distinct immunological mechanisms between adult and paediatric populations. Br J Haematol 109: 130–137.
[65]
Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, et al. (2001) Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 7: 473–485.
[66]
Weerkamp F, Baert MRM, Naber BAE, Koster EEL, de Haas EFE, et al. (2006) Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules. Proc Natl Acad Sci U S A 103: 3322–3326.
[67]
Yu J, Wei M, Becknell B, Trotta R, Liu S, et al. (2006) Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-γ production by human natural killer cells. Immunity 24: 575–590.
[68]
Yang YA, Zhang GM, Feigenbaum L, Zhang YE (2006) Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 9: 445–457.
[69]
Kalies K, Blessenohl M, Nietsch J, Westermann J (2006) T cell zones of lymphoid organs constitutively express Th1 cytokine mRNA: Specific changes during the early phase of an immune response. J Immunol 176: 741–749.
[70]
Laouar Y, Sutterwala FS, Gorelik L, Flavell RA (2005) Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ. Nat Immunol 6: 600–607.
[71]
Park I-K, Shultz LD, Letterio JJ, Gorham JD (2005) TGF-β1 inhibits T-bet induction by IFN-γ in murine CD4+ T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J Immunol 175: 5666–5674.
[72]
Chen ZM, O'Shaughnessy MJ, Gramaglia I, Panoskaltsis-Mortari A, Murphy WJ, et al. (2003) IL-10 and TGF-β induce alloreactive CD4+CD25？ T cells to acquire regulatory cell function. Blood 101: 5076–5083.
[73]
Peng Y, Laouar Y, Li MO, Green EA, Flavell RA (2004) TGF-β regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 101: 4572–4577.
[74]
Marie JC, Letterio JJ, Gavin M, Rudensky AY (2005) TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201: 1061–1067.
[75]
Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, et al. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9: 1144–1150.
[76]
Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL (2002) CD4+CD25+ immunoregulatory T Cells: New therapeutics for graft-versus-host disease. J Exp Med 196: 401–406.
[77]
Taylor PA, Lees CJ, Blazar BR (2002) The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493–3499.
[78]
Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, et al. (2005) TGFβ in allogeneic stem cell transplantation: Friend or foe? Blood 106: 2206–2214.
[79]
Dong M, Blobe GC (2006) Role of transforming growth factor-β in hematological malignancies. Blood 107: 4589–4596.
[80]
Tamura A, Milford EL, Utku N (2005) TIRC7 pathway as a target for preventing allograft rejection. Drug News Perspect 18: 103–108.
[81]
Utku N, Heinemann T, Tullius SG, Bulwin GC, Beinke S, et al. (1998) Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity 9: 509–518.
[82]
Kumamoto Y, Tomschegg A, Bennai-Sanfourche F, Boerner A, Kaser A, et al. (2004) Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice. Am J Transplant 4: 505–514.
[83]
Storek J, Joseph A, Dawson MA, Douek DC, Storer B, et al. (2002) Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation 73: 1154–1158.
[84]
Poulin JF, Sylvestre M, Champagne P, Dion ML, Kettaf N, et al. (2003) Evidence for adequate thymic function but impaired na？ve T-cell survival following allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Blood 102: 4600–4607.
[85]
Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, et al. (2005) Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 115: 930–939.
[86]
Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, et al. (2006) An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 108: 749–755.
